Sec Form 4 Filing - Gavin Robert M. @ BIO-TECHNE Corp - 2017-10-26

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Gavin Robert M. 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Sen. VP Protein Platforms (Last) (First) (Middle) C/O BIO-TECHNE CORPORATION, 614 MCKINLEY PLACE NE 3. Date of Earliest Transaction (MM/DD/YY) 10/26/2017 (Street) MINNEAPOLIS, MN55413 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 1,667 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 1 ) 10/26/2017 A 1,949 ( 2 ) ( 2 ) Common Stock 1,949 $ 0 1,949 D Stock Options (Right to buy) $ 125.05 10/26/2017 A 10,742 ( 2 ) 08/09/2024 Common Stock 10,742 $ 0 10,742 D Stock Options (Right to buy) $ 125.05 10/26/2017 A 14,323 ( 3 ) 08/09/2024 Common Stock 14,323 $ 0 14,323 D Restricted Stock Units ( 4 ) ( 5 ) ( 5 ) Common Stock 1,500 1,500 D Restricted Stock Units ( 1 ) ( 6 ) ( 6 ) Common Stock 2,111 2,111 D Stock Option (Right to Buy) $ 108.49 ( 7 ) 08/07/2022 Common Stock 12,500 12,500 D Stock Option (Right to Buy) $ 108.49 ( 5 ) 08/07/2022 Common Stock 9,375 9,375 D Stock Option (Right to Buy) $ 93.32 ( 8 ) 07/31/2021 Common Stock 10,000 10,000 D Stock Option (Right to Buy) $ 90.25 ( 9 ) 11/30/2021 Common Stock 5,000 5,000 D Stock Options (Right to buy) $ 106.59 ( 6 ) 08/18/2023 Common Stock 13,028 13,028 D Stock Options (Right to buy) $ 106.59 ( 10 ) 08/18/2023 Common Stock 17,371 17,371 D Stock Options (Right to buy) $ 93.32 ( 11 ) 07/31/2021 Common Stock 16,667 16,667 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Gavin Robert M. C/O BIO-TECHNE CORPORATION 614 MCKINLEY PLACE NE MINNEAPOLIS, MN55413 Sen. VP Protein Platforms Signatures /s/ Brenda S. Furlow, attorney in fact for Robert M. Gavin pursuant to Power of Attorney filed here with 10/30/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 2 )Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 3 )Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. ( 4 )Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. ( 5 )Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 6 )Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 7 )3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19. ( 8 )2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18. ( 9 )1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18. ( 10 )Vests 4,343 shares on each 8/18/2017, 8/18/2018 and 8/18/2019 and 4,342 shares on 8/18/2020 ( 11 )Fully exercisable

Remarks: Due to an administrative error, the Form 4 filed by Reporting Person on February 3, 2017 contained a duplicate of the Table II grants reported in the August 22, 2016 Form 4 filing.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.